Join this webinar to examine scale-up optimizations of AAV gene therapy in upstream processing. The featured speaker will explore both process characterization and experimental approaches to better understand key process steps, such as mixing dynamics and transfection cocktail maturation kinetics. Optimization knowledge is introduced into the process to improve yield and recovery at the 2,000 L scale.
Viralgen specializes in the large-scale cGMP production of AAV gene therapy vectors using their proprietary suspension, triple transfection platform. This platform includes the Pro10™ animal origin free and suspension-adapted cell line, a scalable upstream and robust purification process, coupled with full support for fill and finish, QC testing and regulatory guidance from preclinical to commercial requirements.